ArticleNature communications2023
Th17-associated cytokines IL-17 and IL-23 in inflamed skin of Darier disease patients as potential therapeutic targets.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- Rapid improvement of Darier disease with topical roflumilast: A case report.JAAD case reports · 2026Article
- Darier disease-A review highlighting new insights from the Darier Disease International Task Force.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Bimekizumab as an Effective Treatment in Darier Disease: Clinical Outcomes of a Single-Center Retrospective Analysis of Patients Treated with Biologics.Dermatology and therapy · 2026Article
- Consensus Recommendations for Management of Darier Disease: A Practical Approach.Dermatology and therapy · 2026Article
- Failed metabolic adaptation to stress contributes to epidermal cell adhesion defects in Darier disease.Science advances · 2026Article
- Distinct Involvement of IL-17A Signaling in Darier Disease and Hailey-Hailey Disease.The Journal of dermatology · 2026Article
- Dermatology 2.0: Precision medicine for inflammatory skin diseases.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Increased activation of ErbB and NF-κB signalling pathways in Darier disease affected skin.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Review
- Secukinumab in Refractory Generalized Darier's Disease with a 40-Year Disease Duration: A Case Report.Clinical, cosmetic and investigational dermatology · 2026Article
- Interleukin (IL)-17A Inhibitor as a Treatment for Darier Disease in the Pediatric Population.Cureus · 2026Article
- Mimicking Darier Disease In Vitro: A Human Epidermal Organoid Approach.Experimental dermatology · 2025Article
- Efficacy of interleukin-12/23 and interleukin-23 inhibitors in Hailey-Hailey disease.JAAD case reports · 2025Article
- EPHA5 regulates antifungal innate immunity by phosphorylating EPHB2 and Dectin-1.PLoS pathogens · 2025Article
- Review
- Darier disease: Current insights and challenges in pathogenesis and management.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Pruritus and Neuropsychiatric Symptoms Among Patients with Darier Disease-An Overlooked and Interconnected Challenge.Journal of clinical medicine · 2025Article
- Pumping the Breaks on Acantholytic Skin Disorders: Targeting Calcium Pumps, Desmosomes, and Downstream Signaling in Darier, Hailey-Hailey, and Grover Disease.The Journal of investigative dermatology · 2025Review
- Investigating the potential role of T helper 17 cells among women experiencing overweight and obesity and their possible therapeutic targeting of the RORγt molecule.Scientific reports · 2024Article
- Dantrolene corrects cellular disease features of Darier disease and may be a novel treatment.EMBO molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Darier disease (DD) is a rare, inherited multi-organ disorder associated with mutations in the ATP2A2 gene. DD patients often have skin involvement characterized by malodorous, inflamed skin and recurrent, severe infections. Therapeutic options are limited and inadequate for the long-term management of this chronic disease. The aim of this study was to characterize the cutaneous immune infiltrate in DD skin lesions in detail and to identify new therapeutic targets. Using gene and protein expression profiling assays including scRNA sequencing, we demonstrate enhanced expression of Th17-related genes and cytokines and increased numbers of Th17 cells in six DD patients. We provide evidence that targeting the IL-17/IL-23 axis in a case series of three DD patients with monoclonal antibodies is efficacious with significant clinical improvement. As DD is a chronic, relapsing disease, our findings might pave the way toward additional options for the long-term management of skin inflammation in patients with DD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.